Showing 5521-5530 of 5950 results for "".
- Promius Pharma, LLC: Finalist for PM360 Company of the Year Awardhttps://practicaldermatology.com/news/20140828-promius_pharma_llc_finalist_for_pm360_company_of_the_year_award/2459136/Promius Pharma, LLC has been named as a Trailblazer Company of the Year finalist by PM360, a publication that covers the pharmaceutical, biotech and medical device industries. Promius is one of three finalists in the category of Company of the Y
- The American Med Spa Association Launches a New Comprehensive Websitehttps://practicaldermatology.com/news/20140821-the_american_med_spa_association_launches_a_new_comprehensive_website/2459138/The American Med Spa Association launched a new user-friendly website it says will address all industry needs. The new user-friendly website features a more accessible format for members to obtain up to date information on their state's rules and regulations within the medical spa indust
- Dermira Completes $51 Million Financing and Expands Management Team and Board of Directorshttps://practicaldermatology.com/news/20140821-dermira_completes_51_million_financing_and_expands_management_team_and_board_of_directors/2459139/Dermira, a specialty biopharmaceutical focused on dermatology, completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock S
- Acyclovir Muco-Adhesive Buccal Tablet Offers a Novel Approach to Target HSVhttps://practicaldermatology.com/news/20140820-acyclovir_muco-adhesive_buccal_tablet_offers_a_novel_approach_to_target_hsv/2459141/Sitavig® (50mg acyclovir) Muco-Adhesive Buccal Tablet is a new treatment option for recurrent herpes labialis, offering a unique vehicle and delivery system. Sitavig, licensed to Innocutis by BioAlliance Pharma, uses proprietary Lauriad® delivery technology, which delivers a high and sustained conce
- 'Sun Safe' Study: Children Seek Shade if Availablehttps://practicaldermatology.com/news/20140812-sun_safe_study_children_seek_shade_if_available/2459147/A new study by the founder of Sun Safe Soccer reveals nearly two-thirds of children will use shade tents during soccer breaks without any prompting from coaches. The study, published in JAMA Dermatology, was conducted by Ian Maher, M.D., who developed the Sun Safe Soccer skin cancer preve
- Justin Chickles Joins myoscience as Vice President of Commercial Development & Johanna Beckmen Becomes General Manager of Aestheticshttps://practicaldermatology.com/news/20140812-justin_chickles_joins_myoscience_as_vice_president_of_commercial_development__johanna_beckmen_becomes_general_manager_of_aesthetics/2459148/Justin Chickles is now Vice President of Commercial Development and Johanna Beckmen is now promoted to General Manager of Aesthetics of Myoscience, Inc. Chickles Said, "Myoscience's ioveradegrees treatment is poised to become a transformative therapy for patients living with pain.The pas
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101.
- National Call-to-Action on Skin Cancer Preventionhttps://practicaldermatology.com/news/20140806-national_call-to-action_on_skin_cancer_prevention/2459152/The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services' (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. T
- Cynosure Appoints Timothy W. Baker as Presidenthttps://practicaldermatology.com/news/20140730-cynosure_appoints_timothy_w_baker_as_president/2459154/The Board of Directors of Cynosure, Inc., which develops and markets laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, promoted Executive Vice President, Chief Operating Officer and Chief Financial Officer Timothy W. Baker to Presi
- FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLChttps://practicaldermatology.com/news/20140728-aqua_pharmaceuticals_llc_announces_fda_approval_of_acticlate_tablets/2459155/The FDA approved Aqua Pharmaceuticals' Acticlate (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, an oral antibiotics for acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.